Is Fidaxomicin Worth the Cost? An Economic Analysis
Is Fidaxomicin Worth the Cost? An Economic Analysis
About this item
Full title
Author / Creator
Publisher
Oxford: Oxford University Press
Journal title
Language
English
Formats
Publication information
Publisher
Oxford: Oxford University Press
Subjects
More information
Scope and Contents
Contents
Background. In May 2011, the Food and Drug Administration approved fidaxomicin for the treatment of Clostridium difficile infection (CDI). It has been found to be noninferior to vancomycin; however, its cost-effectiveness for the treatment of CDI remains undetermined. Methods. We developed a decision analytic simulation model to determine the econo...
Alternative Titles
Full title
Is Fidaxomicin Worth the Cost? An Economic Analysis
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3719891
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3719891
Other Identifiers
ISSN
1058-4838
E-ISSN
1537-6591
DOI
10.1093/cid/cit346
